222 related articles for article (PubMed ID: 35181782)
1. Lysosomal ceramides regulate cathepsin B-mediated processing of saposin C and glucocerebrosidase activity.
Kim MJ; Jeong H; Krainc D
Hum Mol Genet; 2022 Jul; 31(14):2424-2437. PubMed ID: 35181782
[TBL] [Abstract][Full Text] [Related]
2. Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome.
Ruz C; Barrero FJ; Pelegrina J; Bandrés-Ciga S; Vives F; Duran R
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233303
[TBL] [Abstract][Full Text] [Related]
3. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
4. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
5. Saposin C protects glucocerebrosidase against α-synuclein inhibition.
Yap TL; Gruschus JM; Velayati A; Sidransky E; Lee JC
Biochemistry; 2013 Oct; 52(41):7161-3. PubMed ID: 24070323
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase.
Kim MJ; Kim S; Reinheckel T; Krainc D
JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38329128
[TBL] [Abstract][Full Text] [Related]
7. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
Yang SY; Gegg M; Chau D; Schapira A
Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of Glucocerebrosidase Activity beyond Gaucher Disease: PSAP and LIMP-2 Dysfunctions.
Pavan E; Peruzzo P; Cattarossi S; Bergamin N; Bordugo A; Sechi A; Scarpa M; Biasizzo J; Colucci F; Dardis A
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928321
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
11. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
12. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
13. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
14. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
[TBL] [Abstract][Full Text] [Related]
15. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
[TBL] [Abstract][Full Text] [Related]
16. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation.
Bae EJ; Yang NY; Lee C; Lee HJ; Kim S; Sardi SP; Lee SJ
Exp Mol Med; 2015 Mar; 47(3):e153. PubMed ID: 25813221
[TBL] [Abstract][Full Text] [Related]
17. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
18. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
[TBL] [Abstract][Full Text] [Related]
19. Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency.
Keatinge M; Gegg ME; Watson L; Mortiboys H; Li N; Dunning M; Ailani D; Bui H; van Rens A; Lefeber DJ; Schapira AHV; MacDonald RB; Bandmann O
Dis Model Mech; 2023 Jun; 16(6):. PubMed ID: 36951087
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
Menozzi E; Schapira AHV
CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
